ACUTE LYMPHOBLASTIC LEUKEMIA;
ADVANCED CANCER;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
ARTHRALGIA;
ARTICLE;
BLAST CELL CRISIS;
BLOOD TOXICITY;
BONE MARROW SUPPRESSION;
CANCER CELL CULTURE;
CANCER PATIENT;
CELL PROLIFERATION;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
CYTOGENETICS;
DIARRHEA;
DOSE CALCULATION;
DOSE RESPONSE;
DRUG ACTIVITY;
DRUG APPROVAL;
DRUG BLOOD LEVEL;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG ERUPTION;
DRUG EXCRETION;
DRUG FEVER;
DRUG INDICATION;
DRUG INDUCED HEADACHE;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG POTENCY;
DRUG SAFETY;
DRUG SCREENING;
DRUG TOLERABILITY;
FATIGUE;
FOLLOW UP;
FOOD AND DRUG ADMINISTRATION;
GASTROINTESTINAL HEMORRHAGE;
GENE MUTATION;
HEART ARRHYTHMIA;
HUMAN;
IN VITRO STUDY;
IN VIVO STUDY;
MITOSIS INHIBITION;
MULTIPLE MYELOMA;
NAUSEA;
NEUTROPENIA;
NONHUMAN;
PERIPHERAL EDEMA;
PHILADELPHIA CHROMOSOME POSITIVE CELL;
PLEURA EFFUSION;
PNEUMONIA;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PROTEIN PHOSPHORYLATION;
QT PROLONGATION;
SCID MOUSE;
SOLID TUMOR;
THROMBOCYTOPENIA;
TUMOR LYSIS SYNDROME;
UPREGULATION;
XENOGRAFT;
Bristol-Myers Squibb Company. Bristol-Myers Squibb Submits New Drug Application for Dasatinib. Media Release: 28 Dec 2005. Available from URL: http://www.bms.com
BMS-354825 is a novel orally bioavailable small molecule ABL tyrosine kinase inhibitor that successfully and safely inhibits the kinase activity of multiple imatinib-resistant BCR-ABL isoforms in vitro and in vivo
Mar
Shah NP, Tran C, Lee FY, et al. BMS-354825 is a novel orally bioavailable small molecule ABL tyrosine kinase inhibitor that successfully and safely inhibits the kinase activity of multiple imatinib-resistant BCR-ABL isoforms in vitro and in vivo. 95th Annual Meeting of the American Association for Cancer Research 45: 1299, Mar 2004
BMS-354825 - A potent dual SRC/ABL kinase inhibitor possessing curative efficacy against imatinib sensitive and resistant human CML models in vivo
Mar
Lee FY, Lombardo L, Borzilleri R, et al. BMS-354825 - a potent dual SRC/ABL kinase inhibitor possessing curative efficacy against imatinib sensitive and resistant human CML models in vivo. 95th Annual Meeting of the American Association for Cancer Research 45: 921, Mar 2004
Dasatinib (BMS-354825): A multi-targeted kinase inhibitor with activity against multiple myeloma
16 Nov
Deng Q, Mitsiades N, Negri J, et al. Dasatinib (BMS-354825): a multi-targeted kinase inhibitor with activity against multiple myeloma. Blood 106: 451, No. 11, Part 1, 16 Nov 2005
Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: Results from a phase I dose escalation study
(plus oral presentation) abstr. 1, 16 Nov
Sawyers CL, Shah NP, Kantarjian HM, et al. Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a phase I dose escalation study. Blood 104: 4 (plus oral presentation) abstr. 1, No. 11, Part 1, 16 Nov 2004
Hematologic and cytogenetic response in imatinib-resistant accelerated and blast phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: Results from a phase I dose escalation study
16 Nov
Talpaz M, Kantarjian H, Shah NP, et al. Hematologic and cytogenetic response in imatinib-resistant accelerated and blast phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a phase I dose escalation study. Blood 104: 10, No. 11, Part 1, 16 Nov 2004
Phase I Study Results of Investigational Agent BMS-354825 in Patients with Imatinib-Resistant or Intolerant Chronic Myelogenous Leukemia
Media Release: 5 Dec 2004
Bristol-Myers Squibb Company. Phase I Study Results of Investigational Agent BMS-354825 in Patients With Imatinib-Resistant or Intolerant Chronic Myelogenous Leukemia Presented at the 46th Annual Meeting of the American Society of Hematology. Media Release: 5 Dec 2004. Available from URL: http://www.bms.com
Dasatinib (BMS-354825) in patients with chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: Update of a phase I study
16 Nov
Sawyers CL, Kantarjian H, Shah N, et al. Dasatinib (BMS-354825) in patients with chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: update of a phase I study. Blood 106: 16, No. 11, Part 1, 16 Nov 2005
The American Society of Hematology. New Studies Identify Advances in Treatment Of Chronic Myeloid Leukemia. Media Release: 10 Dec 2005. Available from URL: http:// www.hematology.org
Efficacy of dasatinib in patients with chronic phase Philadelphia chromosome-positive CML resistant or intolerant to imatinib: First results of the CA180013 START-C Phase II Study
16 Nov
Hochhaus A, Baccarani M, Sawyers C, et al. Efficacy of dasatinib in patients with chronic phase Philadelphia chromosome-positive CML resistant or intolerant to imatinib: first results of the CA180013 START-C Phase II Study. Blood 106: 17, No. 11, Part 1, 16 Nov 2005
A phase II study of dasatinib in patients with chronic myeloid leukemia in myeloid blast crisis who are resistant or intolerant to imatinib: First results of the CA180006 START-B Study
plus oral presentation, abstr. 40, 16 Nov
Talpaz M, Rousselot P, Kim DW, et al. A phase II study of dasatinib in patients with chronic myeloid leukemia in myeloid blast crisis who are resistant or intolerant to imatinib: first results of the CA180006 START-B Study. Blood 106: 16 (plus oral presentation), abstr. 40, No. 11, Part 1, 16 Nov 2005
Molecular responses and mutation analysis in imatinib-resistant patients with Philadelphia positive leukemia treated with the dual SCR/ABL kinase inhibitor BMS-354825
Jun
Branford S, Hughes T, Nicoll J, et al. Molecular responses and mutation analysis in imatinib-resistant patients with Philadelphia positive leukemia treated with the dual SCR/ABL kinase inhibitor BMS-354825. Haematologica 90 (Suppl. 2): 47, Jun 2005
